dapagliflozin
astrazeneca
[]
these data provide strong evidence to support the use of an #sglt2i as foundational therapy in virtually all patients with #heartfailure, regardless of the presence or absence of #t2dm, care setting, or ef. #deliver #esccongress 
Cardiologist FACC, FESC | Physician-scientist | Author & Nature Lover. #HeartFailure???????l #HFA & #EACVI HIT Ambassador @escardio | Content Catalyst in @TCTMD